With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

After disappointing trial results for cancer treatments, Mural Oncology announced Wednesday it is cutting 90% of its ...

President Trump’s financial fight with Harvard University risks economic fallout far beyond the ornate gates surrounding ...

Roche’s drug production operations are set to benefit from the company’s updated U.S. strategy, including with “expanded and ...

A developer that specializes in office to lab conversions secured the largest life science lease of 2025 in Boston with a ...

While President Trump and Elon Musk have cut spending on research and grants that fueled the life sciences and climate tech ...

Boston-based Odyssey Therapeutics Inc. filed ... have contributed to the pullback on IPOs in the last few years. Biotech companies have a high rate of failure, he said, and several years ago ...

J&J also raised its full-year revenue guidance to include sales of the psychiatric drug Caplyta, which the company got from ...

Portuguese biotech FairJourney Biologics has acquired South San Francisco antibody R&D facility from Charles River Labs, ...

NORTHAMPTON, MA / ACCESS Newswire / April 4, 2025 / In the biotechnology sector, innovation extends beyond medical discoveries to include approaches for managing environmental impact. For example ...

The company is led by founder and CEO Demis ... New investor RA Capital Management led the Boston-based biotech’s financing. —Abcuro raised $200 million to support ulviprubart, a drug in ...

You can meet a lot of Worcester-educated entrepreneurs, and visit a lot of Worcester-hatched biotech companies — in Boston. Brad McNamara is among them. I first connected with McNamara when he ...